What is IMA stock price today?

IMA (Imagenebio Inc) stock is trading at $4.90 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IMA stock going up or down today?

IMA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IMA stock now?

The decision to buy IMA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IMA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IMA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IMA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IMA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IMA's P/E ratio?

P/E ratio data for IMA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IMA's market cap?

IMA (Imagenebio Inc) has a market capitalization of $0.05 billion, making it a small-cap stock.

What is IMA's price to book ratio?

IMA trades at a price-to-book (P/B) ratio of 0.41, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IMA pay dividends?

IMA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IMA's dividend yield?

IMA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IMA stock a good long-term investment?

IMA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IMA's revenue growth rate?

Revenue growth data for IMA is available on our dashboard with detailed financial statement analysis.

Profitability metrics for IMA are available on our dashboard with complete income statement analysis.

What are the risks of investing in IMA?

Key risks for IMA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IMA compare to its competitors?

Compare IMA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IMA's performance and positioning.

What is IMA's stock price target for 2026?

Our AI model provides price targets for IMA based on fundamental analysis: Bull case $6.37 (+30%), Base case $5.64 (+15%), Bear case $4.41 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IMA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IMA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IMA's next earnings report?

IMA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IMA - Imagenebio Inc

NYSE * Healthcare * Biotechnology

$4.90

+$0.15 (+3.20%)

About Imagenebio Inc

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

IMA Key Statistics

Market Cap

$54.83M

P/B Ratio

0.41

EPS

$-9.64

Employees

How IMA Compares to Peers

IMA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IMA(This stock)	$54.83M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.58B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.56B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.93B	28.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.92B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.88B	20.1	-0%	0.1%	vs BIIB

Imagenebio Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.inmagenebio.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: April 14, 2026 at 7:28 PM EDT

Ready to invest in IMA?

Commission-free trading available. Affiliate links.

IMA Lician Score

5% confidence

4.0/10

Neutral

IMA has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates IMAacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

IMA Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for IMA

Dashboard

Enter a ticker to analyze